Press Offices

Press Offices

SMC Spain amplifies the voices of experts on current topics that provoke controversy. 

¿Qué me ofrece?

The sources that collaborate with SMC Spain will multiply their national and international media impact. Register your office to become part of a directory on this website that journalists can consult. Our guides on communication and science can help you in your daily work.

Icono
Cómo trabajamos

We will rely on you when we contact sources from your organization or when we organize briefing sessions with them. We will provide you with support resources to facilitate your work. You can learn more about our method here

Título qué me ofrece
What We Offer You
Título cómo trabajamos
How We Work

Reactions to the case study of a person who has survived twelve tumours

A study published today in Science Advances describes the case of a person who in less than 40 years of life has developed twelve tumours, five of them malignant, due to inherited mutations in a gene. The research reveals that his  immune system has naturally generated an altered inflammatory response that fights tumours. Understanding the mechanism will be useful to stimulate this type of response in other cases, according to the CNIO authors of the study.

0

Reaction to study looking at neurodevelopment of children born in first year of pandemic

A systematic review and meta-analysis published in JAMA Network Open examines whether there is an association between newborn exposure to SARS-CoV-2 and impaired neurodevelopment compared to those born before the pandemic. Neurodevelopment in the first year of life was not modified by being born or growing up during the covid-19 pandemic or by gestational exposure to SARS-CoV-2. However, the authors appreciated that, regardless of whether maternal infection was present, the pandemic was associated with a risk of delayed communication in these infants.

0

Reaction to study looking at thrombus risk after vaccination with AstraZeneca and Janssen

A study published in the BMJ looks at the risk of thromboembolic events associated with different covid-19 vaccines, both adenovirus- and mRNA-based. Its results are based on data collected from more than 10 million adults in France, Germany, the Netherlands, Spain, the UK and the US who received at least one dose of a covid-19 vaccine from December 2020 to mid-2021.

0